Karin Jordan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Karin Jordan has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Axel Grothey
Internal Medicine IV, Hematology/Oncology, Martin‐Luther‐University Halle/Wittenberg, Halle/Saale, Germany
3 shared publicationsH.-J. Schmoll
Department of Oncology/Hematology, University of Halle, Halle, Germany
3 shared publicationsThomas Kegel
3 shared publicationsTimo Behlendorf
3 shared publicationsA. Grothey
Department of Oncology, Mayo Clinic, Rochester, MN, USA
2 shared publications- Alexey Surov
Department of Radiology, Neuroradiology and Nuclear Medicine, Johannes Wesling Hospital, Ruhr University Bochum, Minden, Germany
2 shared publications
Latest Publications
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 10090
Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).
10090 Background: Co-administration of multiple antiemetics that inhibit several molecular pathways involved in emesis is required to optimize CINV control in patients receiving highly emetogenic chemotherapy (HEC). NEPA, a novel fixed combination of a highly selective NK1 receptor antagonist (RA), netupitant (300 mg), and palonosetron (PALO 0.50 mg), a pharmacologically distinct 5-HT3RA, has shown superior CINV prevention compared to PALO in cisplatin and AC-based settings. This study is the first head-to-head comparison of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen, with the primary objective being to demonstrate non-inferiority in preventing CINV. Methods: This randomized, double-blind, parallel group Phase III study conducted in an Asian population was designed to compare efficacy and safety of a single oral dose of NEPA with a 3-day oral APR/GRAN regimen in chemotherapy-naïve patients receiving cisplatin-based HEC. All patients also received oral dexamethasone (DEX) on days 1-4. The primary efficacy endpoint was complete response (CR: no emesis, no rescue medication) during the overall (0-120 h) phase. Non-inferiority was defined as a lower 95% CI greater than the non-inferiority margin set at -10%. Secondary efficacy endpoints included no emesis and no significant nausea (NSN: < 25mm on 100mm VAS). Results: Treatment groups were comparable for the 828 patients analyzed: predominantly male (71%); mean age 54.5 years; ECOG 0-1 (98%); lung cancer (58%). NEPA demonstrated non-inferiority to APR/GRAN for overall CR; no emesis and NSN rates favored NEPA. Most frequent study drug-related adverse events (AEs) for NEPA included constipation (8.0%) and hiccups (2.7%). The type/incidence/severity of AEs were similar for NEPA and APR/GRAN. Conclusions: In this first study comparing NK1RA regimens and 4 days of DEX, NEPA administered only on day 1 was non-inferior to a 3-day oral APR/GRAN regimen in preventing CINV associated with HEC. [Table: see text]
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 10090
Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).
10090 Background: Co-administration of multiple antiemetics that inhibit several molecular pathways involved in emesis is required to optimize CINV control in patients receiving highly emetogenic chemotherapy (HEC). NEPA, a novel fixed combination of a highly selective NK1 receptor antagonist (RA), netupitant (300 mg), and palonosetron (PALO 0.50 mg), a pharmacologically distinct 5-HT3RA, has shown superior CINV prevention compared to PALO in cisplatin and AC-based settings. This study is the first head-to-head comparison of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen, with the primary objective being to demonstrate non-inferiority in preventing CINV. Methods: This randomized, double-blind, parallel group Phase III study conducted in an Asian population was designed to compare efficacy and safety of a single oral dose of NEPA with a 3-day oral APR/GRAN regimen in chemotherapy-naïve patients receiving cisplatin-based HEC. All patients also received oral dexamethasone (DEX) on days 1-4. The primary efficacy endpoint was complete response (CR: no emesis, no rescue medication) during the overall (0-120 h) phase. Non-inferiority was defined as a lower 95% CI greater than the non-inferiority margin set at -10%. Secondary efficacy endpoints included no emesis and no significant nausea (NSN: < 25mm on 100mm VAS). Results: Treatment groups were comparable for the 828 patients analyzed: predominantly male (71%); mean age 54.5 years; ECOG 0-1 (98%); lung cancer (58%). NEPA demonstrated non-inferiority to APR/GRAN for overall CR; no emesis and NSN rates favored NEPA. Most frequent study drug-related adverse events (AEs) for NEPA included constipation (8.0%) and hiccups (2.7%). The type/incidence/severity of AEs were similar for NEPA and APR/GRAN. Conclusions: In this first study comparing NK1RA regimens and 4 days of DEX, NEPA administered only on day 1 was non-inferior to a 3-day oral APR/GRAN regimen in preventing CINV associated with HEC. [Table: see text]
- Open Access
- 16 April 2011
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 30 (1) , 42
Promising cytotoxic activity profile of fermented wheat germ extract (Avemar®) in human cancer cell lines
Fermented wheat germ extract (FWGE) is currently used as nutrition supplement for cancer patients. Limited recent data suggest antiproliferative, antimetastatic and immunological effects which were at least in part exerted by two quinones, 2-methoxy benzoquinone and 2,6-dimethoxybenzquinone as ingredients of FWGE. These activity data prompted us to further evaluate the in vitro antiproliferative activity of FWGE alone or in combination with the commonly used cytotoxic drugs 5-FU, oxaliplatin or irinotecan in a broad spectrum of human tumor cell lines. We used the sulforhodamine B assay to determine dose response relationships and IC50-values were calculated using the Hill equation. Drug interaction of simultaneous and sequential drug exposure was estimated using the model of Drewinko and potential clinical activity was assessed by the model of relative antitumor activity (RAA). Apoptosis was detected by DNA gel electrophoresis. FWGE induced apoptosis and exerted significant antitumor activity in a broad spectrum of 32 human cancer cell lines. The highest activity was found in neuroblastoma cell lines with an average IC50 of 0.042 mg/ml. Furthermore, IC50-range was very narrow ranging from 0.3 mg/ml to 0.54 mg/ml in 8 colon cancer cell lines. At combination experiments in colon cancer cell lines when FWGE was simultaneously applied with either 5-FU, oxaliplatin or irinotecan we observed additive to synergistic drug interaction, particularly for 5-FU. At sequential drug exposure with 5-FU and FWGE the observed synergism was abolished. Taken together, FWGE exerts significant antitumor activity in our tumor model. Simultaneous drug exposure with FWGE and 5-FU, oxaliplatin or irinotecan yielded in additive to synergistic drug interaction. However, sequential drug exposure of 5-FU and FWGE in colon cancer cell lines appeared to be schedule-dependent (5-FU may precede FWGE). Further evaluation of FWGE as a candidate for clinical combination drug regimens appeared to be warranted.
- 16 April 2011
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 30 (1) , 42
Open AccessPromising cytotoxic activity profile of fermented wheat germ extract (Avemar®) in human cancer cell lines
Fermented wheat germ extract (FWGE) is currently used as nutrition supplement for cancer patients. Limited recent data suggest antiproliferative, antimetastatic and immunological effects which were at least in part exerted by two quinones, 2-methoxy benzoquinone and 2,6-dimethoxybenzquinone as ingredients of FWGE. These activity data prompted us to further evaluate the in vitro antiproliferative activity of FWGE alone or in combination with the commonly used cytotoxic drugs 5-FU, oxaliplatin or irinotecan in a broad spectrum of human tumor cell lines. We used the sulforhodamine B assay to determine dose response relationships and IC50-values were calculated using the Hill equation. Drug interaction of simultaneous and sequential drug exposure was estimated using the model of Drewinko and potential clinical activity was assessed by the model of relative antitumor activity (RAA). Apoptosis was detected by DNA gel electrophoresis. FWGE induced apoptosis and exerted significant antitumor activity in a broad spectrum of 32 human cancer cell lines. The highest activity was found in neuroblastoma cell lines with an average IC50 of 0.042 mg/ml. Furthermore, IC50-range was very narrow ranging from 0.3 mg/ml to 0.54 mg/ml in 8 colon cancer cell lines. At combination experiments in colon cancer cell lines when FWGE was simultaneously applied with either 5-FU, oxaliplatin or irinotecan we observed additive to synergistic drug interaction, particularly for 5-FU. At sequential drug exposure with 5-FU and FWGE the observed synergism was abolished. Taken together, FWGE exerts significant antitumor activity in our tumor model. Simultaneous drug exposure with FWGE and 5-FU, oxaliplatin or irinotecan yielded in additive to synergistic drug interaction. However, sequential drug exposure of 5-FU and FWGE in colon cancer cell lines appeared to be schedule-dependent (5-FU may precede FWGE). Further evaluation of FWGE as a candidate for clinical combination drug regimens appeared to be warranted.
- 13 September 2010
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (6) , 784-789
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (highdose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination
Complete protection from nausea/vomiting is currently achieved in a minority of patients receiving high-dose chemotherapy (HDC). Currently the use of 5-HT3-antagonists and dexamethasone (DEX) represents the standard of care. The role of the NK-1-antagonist aprepitant in HDC remains to be better defined. A total of 64 patients undergoing multiple days of HDC received granisetron, DEX plus aprepitant during chemotherapy. After the end of chemotherapy aprepitant plus DEX was given for a further 2 days. Primary end point was CR defined as no vomiting and no use of rescue medication in the overall phase (day 1 until 5 days after end of chemotherapy). Acute/delayed and overall CR were achieved in 83%/70% and 63%, respectively. Acute and delayed nausea were observed in 20 and 38% of the patients. The tolerability of the aprepitant regimen over 4–5 days was comparable with the 3-day antiemetic regimen. In our study, aprepitant demonstrated good tolerability. Taking into account the methodological constraints of comparing our results with those from the available literature, the addition of aprepitant to the antiemetic treatment regimen may provide improved prevention of chemotherapy-induced nausea and vomiting during HDC.
- 13 September 2010
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (6) , 784-789
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (highdose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination
Complete protection from nausea/vomiting is currently achieved in a minority of patients receiving high-dose chemotherapy (HDC). Currently the use of 5-HT3-antagonists and dexamethasone (DEX) represents the standard of care. The role of the NK-1-antagonist aprepitant in HDC remains to be better defined. A total of 64 patients undergoing multiple days of HDC received granisetron, DEX plus aprepitant during chemotherapy. After the end of chemotherapy aprepitant plus DEX was given for a further 2 days. Primary end point was CR defined as no vomiting and no use of rescue medication in the overall phase (day 1 until 5 days after end of chemotherapy). Acute/delayed and overall CR were achieved in 83%/70% and 63%, respectively. Acute and delayed nausea were observed in 20 and 38% of the patients. The tolerability of the aprepitant regimen over 4–5 days was comparable with the 3-day antiemetic regimen. In our study, aprepitant demonstrated good tolerability. Taking into account the methodological constraints of comparing our results with those from the available literature, the addition of aprepitant to the antiemetic treatment regimen may provide improved prevention of chemotherapy-induced nausea and vomiting during HDC.
- 9 September 2010
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 19 (S1) , 37-42
Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009
Only a few studies have been carried out in children on the prevention of chemotherapy-induced nausea and vomiting (CINV). 5-HT3 receptor antagonists have been shown to be more efficacious and less toxic than metoclopramide, phenothiazines and cannabinoids. Most dose studies are available for the 5-HT3 receptor antagonists ondansetron and granisetron. The new 5-HT3 receptor antagonist palonosetron was evaluated in one comparative study so far showing promising activity. Combinations of a 5-HT3 receptor antagonist and dexamethasone showed increased efficacy with respect to a 5-HT3 receptor antagonist alone. All paediatric patients receiving chemotherapy of high or moderate emetogenic potential should receive a combination of a 5-HT3 receptor antagonist and dexamethasone to prevent acute emesis. No studies have specifically evaluated antiemetic drugs in the prevention of chemotherapy-induced delayed and anticipatory emesis in children. The role of the NK1 receptor antagonists in children has to be further investigated, although one small study is published so far, showing promising activity in the prevention of CINV with aprepitant. The new proposed guideline from the Multinational Association of Supportive Care in Cancer and the European Society of Clinical Oncology summarises the updated data from the literature and takes into consideration the existing guidelines.
- 9 September 2010
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 19 (S1) , 37-42
Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009
Only a few studies have been carried out in children on the prevention of chemotherapy-induced nausea and vomiting (CINV). 5-HT3 receptor antagonists have been shown to be more efficacious and less toxic than metoclopramide, phenothiazines and cannabinoids. Most dose studies are available for the 5-HT3 receptor antagonists ondansetron and granisetron. The new 5-HT3 receptor antagonist palonosetron was evaluated in one comparative study so far showing promising activity. Combinations of a 5-HT3 receptor antagonist and dexamethasone showed increased efficacy with respect to a 5-HT3 receptor antagonist alone. All paediatric patients receiving chemotherapy of high or moderate emetogenic potential should receive a combination of a 5-HT3 receptor antagonist and dexamethasone to prevent acute emesis. No studies have specifically evaluated antiemetic drugs in the prevention of chemotherapy-induced delayed and anticipatory emesis in children. The role of the NK1 receptor antagonists in children has to be further investigated, although one small study is published so far, showing promising activity in the prevention of CINV with aprepitant. The new proposed guideline from the Multinational Association of Supportive Care in Cancer and the European Society of Clinical Oncology summarises the updated data from the literature and takes into consideration the existing guidelines.
- Open Access
- 15 March 2010
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 45 (12) , 1704-1709
Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study
We evaluated the feasibility and toxicity of bevacizumab in combination with sequential high-dose (HD) ifosfamide, carboplatin and etoposide refractory to standard chemotherapy in patients with sarcoma and germ cell cancer (GCC). Sixteen patients (13 sarcomas, 3 GCC) received SD-ICE followed by 4 cycles of HD-ICE, qd22 with stem cell support in combination with bevacizumab. All 16 patients were evaluable for toxicity and efficacy, and received 51 cycles (median 3.3). There was no increase in toxicity except of a relatively high incidence of ifosfamide encephalopathy in 17 cycles when compared with previous HD-ICE protocols. One almost complete response in the patient with GCC, previously progressive with three preceding protocols, was observed. Six patients had a partial response (sarcoma 4/13 patients; GCC 2/3 patients), and five patients stable disease (sarcoma 5/13 patients). The median PFS/OS for sarcoma was 5 months (confidence interval (CI): 3.1-6.9) and 13 months (CI: 3.6-24.4), respectively. To our knowledge, this is the first report of the addition of bevacizumab to HD-ICE. This combination did not show new unexpected toxicities except for a relatively high rate of ifosfamide encephalopathy. The efficacy in these heavily pretreated patients including possible reversal of chemotherapy resistance by the addition of bevacizumab indicates a possible potential of bevacizumab in this combination.
- 15 March 2010
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 45 (12) , 1704-1709
Open AccessBevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study
We evaluated the feasibility and toxicity of bevacizumab in combination with sequential high-dose (HD) ifosfamide, carboplatin and etoposide refractory to standard chemotherapy in patients with sarcoma and germ cell cancer (GCC). Sixteen patients (13 sarcomas, 3 GCC) received SD-ICE followed by 4 cycles of HD-ICE, qd22 with stem cell support in combination with bevacizumab. All 16 patients were evaluable for toxicity and efficacy, and received 51 cycles (median 3.3). There was no increase in toxicity except of a relatively high incidence of ifosfamide encephalopathy in 17 cycles when compared with previous HD-ICE protocols. One almost complete response in the patient with GCC, previously progressive with three preceding protocols, was observed. Six patients had a partial response (sarcoma 4/13 patients; GCC 2/3 patients), and five patients stable disease (sarcoma 5/13 patients). The median PFS/OS for sarcoma was 5 months (confidence interval (CI): 3.1-6.9) and 13 months (CI: 3.6-24.4), respectively. To our knowledge, this is the first report of the addition of bevacizumab to HD-ICE. This combination did not show new unexpected toxicities except for a relatively high rate of ifosfamide encephalopathy. The efficacy in these heavily pretreated patients including possible reversal of chemotherapy resistance by the addition of bevacizumab indicates a possible potential of bevacizumab in this combination.
- 31 August 2009
- Published by Hindawi Limited in European Journal of Cancer Care
- Vol. 19 (5) , 603-609
Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting
To assess whether prechemotherapy quality of life (QoL) factors and certain coping strategies are associated with postchemotherapy nausea and vomiting (PCNV). A total of 43 chemotherapy-naïve patients scheduled to receive anti-emetic prophylaxis were enrolled in this study. QoL parameters were measured by a modified EORTC Quality of Life Questionnaire (QLQ-30). In addition, questions regarding active or passive coping strategies were asked 1 day before chemotherapy. Prechemotherapy QoL factors, coping strategies as well as other patient, disease and treatment variables were compared between the groups of patients with or without PCNV. The univariate analysis identified four QoL parameters, 'tiredness', 'impairment of daily life by pain', 'sensation of abdominal pressure and fullness' and 'impairment of social activities' as associated with PCNV. No association was found between coping strategies and PCNV. In the multivariate analysis, the factors 'impairment of social activities' and 'sensation of abdominal pressure and fullness' remained significant. Specific pretreatment QoL parameters are associated with the risk to develop PCNV. Thus, in addition to other established risk factors for PCNV, patients should be screened for these QoL factors in order to improve the control of PCNV and facilitate the selection of appropriate, individualised anti-emetic prophylaxes.
- 31 August 2009
- Published by Hindawi Limited in European Journal of Cancer Care
- Vol. 19 (5) , 603-609
Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting
To assess whether prechemotherapy quality of life (QoL) factors and certain coping strategies are associated with postchemotherapy nausea and vomiting (PCNV). A total of 43 chemotherapy-naïve patients scheduled to receive anti-emetic prophylaxis were enrolled in this study. QoL parameters were measured by a modified EORTC Quality of Life Questionnaire (QLQ-30). In addition, questions regarding active or passive coping strategies were asked 1 day before chemotherapy. Prechemotherapy QoL factors, coping strategies as well as other patient, disease and treatment variables were compared between the groups of patients with or without PCNV. The univariate analysis identified four QoL parameters, 'tiredness', 'impairment of daily life by pain', 'sensation of abdominal pressure and fullness' and 'impairment of social activities' as associated with PCNV. No association was found between coping strategies and PCNV. In the multivariate analysis, the factors 'impairment of social activities' and 'sensation of abdominal pressure and fullness' remained significant. Specific pretreatment QoL parameters are associated with the risk to develop PCNV. Thus, in addition to other established risk factors for PCNV, patients should be screened for these QoL factors in order to improve the control of PCNV and facilitate the selection of appropriate, individualised anti-emetic prophylaxes.
- 23 July 2009
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 17 (12) , 1543-1552
Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial
The purpose of this present study was to evaluate Self-care Improvement through Oncology Nursing (SCION) program to reduce distressing anorexia, nausea, and emesis (ANE) in cancer patients undergoing chemotherapy. Two hundred eight patients receiving chemotherapy with moderate to high emetogenic potential participated in a cluster randomized trial on 14 wards in two German university hospitals. Additionally to standard antiemetic treatment, patients from the intervention wards received the SCION program consisting of four modules: advisory consultation, optimizing emesis prophylaxis, nutrition counseling, and relaxation. Patients from the control group received standard antiemetic treatment and standard care. Primary outcome was the group difference in ANE intensity assessed by Common Terminology Criteria for adverse events (CTCAE). The SCION program did not result in a significant difference in the incidence of ANE symptoms as compared to standard care: mean difference on CTCAE scale was 0.24 pts (95%CI, −1.17 to 1.66 pts; P = 0.733). No difference could be found regarding patients’ knowledge of side effects, self-care interventions, and agency. Health-related quality of life was significantly better for patients in the control group (mean difference 10.2 pts; 95%CI, 1.9 to 18.5; P = 0.017). Contrary to our expectations, the groups did not differ in ANE intensity caused by the overall low acute or delayed symptom intensity. Symptom hierarchy in cancer patients alters and challenges nursing interventions targeting the patients’ self-care strategies.
- 23 July 2009
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 17 (12) , 1543-1552
Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial
The purpose of this present study was to evaluate Self-care Improvement through Oncology Nursing (SCION) program to reduce distressing anorexia, nausea, and emesis (ANE) in cancer patients undergoing chemotherapy. Two hundred eight patients receiving chemotherapy with moderate to high emetogenic potential participated in a cluster randomized trial on 14 wards in two German university hospitals. Additionally to standard antiemetic treatment, patients from the intervention wards received the SCION program consisting of four modules: advisory consultation, optimizing emesis prophylaxis, nutrition counseling, and relaxation. Patients from the control group received standard antiemetic treatment and standard care. Primary outcome was the group difference in ANE intensity assessed by Common Terminology Criteria for adverse events (CTCAE). The SCION program did not result in a significant difference in the incidence of ANE symptoms as compared to standard care: mean difference on CTCAE scale was 0.24 pts (95%CI, −1.17 to 1.66 pts; P = 0.733). No difference could be found regarding patients’ knowledge of side effects, self-care interventions, and agency. Health-related quality of life was significantly better for patients in the control group (mean difference 10.2 pts; 95%CI, 1.9 to 18.5; P = 0.017). Contrary to our expectations, the groups did not differ in ANE intensity caused by the overall low acute or delayed symptom intensity. Symptom hierarchy in cancer patients alters and challenges nursing interventions targeting the patients’ self-care strategies.
- 31 May 2009
- Published by Springer Nature in Die Innere Medizin
- Vol. 50 (7) , 887-894
Neue antiemetische Strategien – nicht nur in der Onkologie
Übelkeit und Erbrechen zählen zu den häufigsten Symptomen im klinischen Alltag. Die korrekte Diagnose ihrer Ursachen setzt die Kenntnis pathophysiologischer Hintergründe des Erbrechens und häufig eine interdisziplinäre Herangehensweise voraus. Das breite Spektrum emetogener Ursachen (labyrinthär, infektiös, mechanisch, medikamentös, hormonell) erfordert neben kausalen Therapieansätzen meist auch eine medikamentöse symptomorientierte Beschwerdelinderung. Dafür stehen mehrere, im Wirkmechanismus und antiemetischen Potenzial unterschiedliche Substanzklassen zur Verfügung. Die Festlegung der antiemetischen Therapiestrategie erfolgt jeweils individuell und berücksichtigt neben der Ursache des Erbrechens den rezeptorspezifischen Wirkmechanismus der Substanz mit den sich daraus ergebenden Nebenwirkungen. Obwohl in den letzten Jahren neuere Substanzklassen wie 5-HT3-Rezeptor- und Neurokinin-1-Rezeptorantagonisten zunehmend an Bedeutung gewonnen haben, sind herkömmliche und langjährig erfolgreich angewandte Antiemetika weiterhin unverzichtbar. Nausea and vomiting are common symptoms in daily clinical practice. For appropriate diagnostics the knowledge of the pathopysiologic origin of nausea and vomiting is indispensable. Furthermore the diagnostic pathway usually has to be approached by an interdisciplinary team. Due to the broad spectrum of emetogenic causes several symptom-based treatment strategies are nowadays available. These include several kinds of antiemetics with different mechanisms of action and with an varying antiemetic potential. The antiemetic strategy is based on individual patient factors as well as on the receptor specific mechanism of action of the antiemetic drug and also the expected side effects. A number of modern antiemetic agents are available for the management of nausea and vomiting, including 5-HT3-receptor antagonists and NK1 receptor antagonists. However, other conventional antiemetic drugs are still in use and should not be underestimated.
- 31 May 2009
- Published by Springer Nature in Die Innere Medizin
- Vol. 50 (7) , 887-894
Neue antiemetische Strategien – nicht nur in der Onkologie
Übelkeit und Erbrechen zählen zu den häufigsten Symptomen im klinischen Alltag. Die korrekte Diagnose ihrer Ursachen setzt die Kenntnis pathophysiologischer Hintergründe des Erbrechens und häufig eine interdisziplinäre Herangehensweise voraus. Das breite Spektrum emetogener Ursachen (labyrinthär, infektiös, mechanisch, medikamentös, hormonell) erfordert neben kausalen Therapieansätzen meist auch eine medikamentöse symptomorientierte Beschwerdelinderung. Dafür stehen mehrere, im Wirkmechanismus und antiemetischen Potenzial unterschiedliche Substanzklassen zur Verfügung. Die Festlegung der antiemetischen Therapiestrategie erfolgt jeweils individuell und berücksichtigt neben der Ursache des Erbrechens den rezeptorspezifischen Wirkmechanismus der Substanz mit den sich daraus ergebenden Nebenwirkungen. Obwohl in den letzten Jahren neuere Substanzklassen wie 5-HT3-Rezeptor- und Neurokinin-1-Rezeptorantagonisten zunehmend an Bedeutung gewonnen haben, sind herkömmliche und langjährig erfolgreich angewandte Antiemetika weiterhin unverzichtbar. Nausea and vomiting are common symptoms in daily clinical practice. For appropriate diagnostics the knowledge of the pathopysiologic origin of nausea and vomiting is indispensable. Furthermore the diagnostic pathway usually has to be approached by an interdisciplinary team. Due to the broad spectrum of emetogenic causes several symptom-based treatment strategies are nowadays available. These include several kinds of antiemetics with different mechanisms of action and with an varying antiemetic potential. The antiemetic strategy is based on individual patient factors as well as on the receptor specific mechanism of action of the antiemetic drug and also the expected side effects. A number of modern antiemetic agents are available for the management of nausea and vomiting, including 5-HT3-receptor antagonists and NK1 receptor antagonists. However, other conventional antiemetic drugs are still in use and should not be underestimated.
- Open Access
- 1 May 2009
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. 5 (2) , 361-366
Anthracycline extravasation injuries: management with dexrazoxane
Anthracycline extravasation injuries: management with dexrazoxane Karin Jordan, Timo Behlendorf, Franziska Mueller, Hans-Joachim SchmollClinic for Internal Medicine IV, Department for Oncology and Haematology, University Hospital Halle, Halle, Germany The application of anthracyclines in anticancer therapy may result in accidental extravasation injury and can be a serious complication of their use. Tissue necrosis with skin ulceration is a possible outcome in the inadvertent extravasation of anthracyclines during intravenous administration. Until recently, there has been no effective treatment against the devastating effect of extravasated anthracycline. Preclinical and clinical studies are leading to the clinical implementation of dexrazoxane as the first and only proven antidote in anthracycline extravasation. In two multicenter studies dexrazoxane has proven to be highly effective in preventing skin necrosis and ulceration. This review focuses on the development and management of dexrazoxane in anthracycline extravasation injuries. Keywords: dexrazoxane, extravasation, necrosis, anthracyclines
- 1 May 2009
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. 5 (2) , 361-366
Open AccessAnthracycline extravasation injuries: management with dexrazoxane
Anthracycline extravasation injuries: management with dexrazoxane Karin Jordan, Timo Behlendorf, Franziska Mueller, Hans-Joachim SchmollClinic for Internal Medicine IV, Department for Oncology and Haematology, University Hospital Halle, Halle, Germany The application of anthracyclines in anticancer therapy may result in accidental extravasation injury and can be a serious complication of their use. Tissue necrosis with skin ulceration is a possible outcome in the inadvertent extravasation of anthracyclines during intravenous administration. Until recently, there has been no effective treatment against the devastating effect of extravasated anthracycline. Preclinical and clinical studies are leading to the clinical implementation of dexrazoxane as the first and only proven antidote in anthracycline extravasation. In two multicenter studies dexrazoxane has proven to be highly effective in preventing skin necrosis and ulceration. This review focuses on the development and management of dexrazoxane in anthracycline extravasation injuries. Keywords: dexrazoxane, extravasation, necrosis, anthracyclines
- 1 May 2009
- Published by Elsevier in European Journal of Cancer
- Vol. 45 (7) , 1184-1187
Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy
- 1 May 2009
- Published by Elsevier in European Journal of Cancer
- Vol. 45 (7) , 1184-1187
Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy